Sage Journals: Discover world-class research

Abstract

Background: Chemotherapy-induced peripheral neuropathy (CIPN) has no cure, but acupuncture may provide relief through its known neuromodulation or neuroendocrine adjustment. This review aimed to assess the efficacy of acupuncture in treating CIPN. Method: A literature review following the PRISMA Statement was performed, searching 7 databases from inception through August 2019. All studies were clinical trials of the effect of acupuncture on CIPN. The methodological quality of these trials was assessed using Cochrane criteria; meta-analysis software (RevMan 5.2) was used to analyze the data. Data Sources: The databases searched were the following: MEDLINE (Ovid), Embase, Cochrane CENTRAL, Scopus, World Health Organization International Clinical Trials Registry Platform, CNKI (China National Knowledge Infrastructure), and Wanfang Med Online. Results: We examined 386 cancer patients from 6 randomized control trials, which had high quality, based on the modified Jadad scale. Meta-analysis showed that acupuncture led to significant improvements in pain scores (−1.21, 95% confidence interval [CI] = −1.61 to −0.82, P < .00001) and nervous system symptoms based on Functional Assessment of Cancer Therapy/Neurotoxicity questionnaire scores (−2.02, 95% CI = −2.21 to −1.84, P < .00001). No significant change was noted in nerve conduction velocity (1.58, 95% CI = −2.67 to 5.83, P = .47). Conclusion: Acupuncture can effectively relieve CIPN pain and functional limitation. The limited number of subjects warrants a larger scale study.

Keywords

acupuncture cancer chemotherapy neuropathy systematic review

Introduction

Neuropathic pain related to chemotherapy (chemotherapy-induced peripheral neuropathy [CIPN]) is a troubling problem in cancer treatment; an estimated 30% to 40% of patients have been treated with at least one of the offending agents.¹ Some cytostatic groups are especially involved, such as bortezomib, platinum drugs, taxanes, vinca alkaloids, and thalidomide.^2,3 Each of these drugs induces CIPN, although through different mechanisms; for example, taxanes are tubulin inhibitors that damage neuronal axons, while platinum analogs accumulate in the cell bodies of sensory nerves and damage DNA.⁴

The clinical characteristics of CIPN include paresthesia (tingling, burning sensation), hyperalgesia (sensitive to noxious stimulation), allodynia (pain induced by a normally innocuous stimulation), and decreased physical activity.⁵ Some patients also experience motor symptoms, such as dropping items, splaying fingers, and inability to complete normal daily activities.⁶ Some patients may even withdraw from chemotherapy or receive reduced doses, which in turn decreases the treatment efficacy. Accordingly, multi-integrated therapies are used in these populations, such as fish oil,⁷ vitamin B,⁸ glutamines,^9,10 and acupuncture,^11,12 all of which have been reported to show some benefit in reducing CIPN. Acupuncture, which has drawn researchers’ attention in recent years, is widely accepted for its noninvasiveness and safety. In Chinese medicine theory, acupuncture works by regulating the imbalance of meridians, promoting the Qi (energy) over our body; in western medicine, acupuncture has been shown to work by adjusting neurophysiologic and neurohormonal activitiy.^13,14 Although the interpretation of how acupuncture works varies by cultural context, researchers agree on its potential to alleviate some symptoms that are hard to control with conventional treatment.

In fact, many integrative oncologists have adopted acupuncture as a complementary or alternative medicine. Furthermore, evidence-based research increasingly shows that acupuncture can relieve many uncontrollable symptoms, including cancer pain^15,16 (noted as evidence level I), chemotherapy-related side effects,^1,17,18 hot flush or arthralgia related to hormone therapy,^19,20 and xerostomia relevant to radiotherapy.^21,22 With regard to neuropathy, acupuncture has been widely used in diabetes-related neuropathy^23,24 and carpal tunnel syndrome,^25,26 as well as CIPN.

There are no large-scale studies or systematic reviews of the effectiveness of acupuncture in alleviating CIPN. To clarify this point, we conducted a systematic review and meta-analysis, providing more objective data for applying acupuncture to chemotherapy-related neuropathy in the future.

Methods

Data Sources and Searches

The conduct of this systematic review complied with the PRISMA Statement^27,28 to ensure transparent and complete reporting. Seven databases were searched for relevant randomized controlled trials (RCTs), from their inception dates to August 2019: MEDLINE (through the Ovid interface, including epub ahead of print, in-process, and other non-indexed citations), Embase, Cochrane CENTRAL, Scopus, and World Health Organization International Clinical Trials Registry Platform (ICTRP), CNKI (China National Knowledge Infrastructure), and Wanfang Med Online. The reference lists of eligible articles were reviewed to identify additional studies for possible inclusion. We also established e-mail alerts to identify newly released studies from the different databases, which fell within the scope of our review.

The key concepts used in the search (neuropathy, chemotherapy, and acupuncture) included their synonyms (116 English free-text terms plus truncation symbols when appropriate, and 16 Chinese free-text terms) and controlled vocabulary (25 MeSH [medical subject headings] terms and 21 Emtree terms). We adopted highly sensitive search syntaxes to identifying RCTs. Appendix 1 (available online) shows the search strategy.

Eligibility Criteria

All eligible studies examined patients afflicted with CIPN and measured the severity of neuropathy and quality of life. Only studies that used a true needle or electroacupuncture were included; those which adopted transcutaneous electrical nerve stimulation or other acupoint stimulation such as laser acupuncture were excluded. To improve consistency, only studies that measured the Brief Pain Inventory–Short Form worst pain score (BPI-SF), the Functional Assessment of Cancer Therapy/Neurotoxicity (FACT-NXT) score,^29,30 and nerve conduction velocity (NCV) were subjected to meta-analysis.

Study and Data Extraction

Searches of the 7 databases and additional sources led to the identification of 2405 potentially relevant articles, 2399 of which were ultimately excluded. The titles and abstracts that fulfilled the criteria of our study were independently read by 2 reviewers (Chien and Liu), and the full texts of articles that met these criteria were obtained. Final decisions on inclusion were made after examination of the full articles. In cases of duplicate publications, the most recent and complete versions were selected. Among the excluded records, 611 articles were excluded because of duplication, 1726 titles/abstracts were irrelevant, and 62 full texts were non-RCTs, non-English/Chinese, clinical trials in progress, reported a duplicate population, were conference abstracts or had no matched coverage or were clinical registers that did not provide enough information for analysis, or theses. We also contacted some authors to ensure that studies that had appeared only as abstracts at conferences could be included if completed data were available. The study selection flowchart is shown in Figure 1. Six RCTs were included: Molassiotis et al,³¹ Greenlee et al,³² Han et al,³³ Zhang et al,³⁴ Lu et al,³⁵ and Rostock et al³⁶; 5 of these were included in the meta-analysis. The characteristic and results of the included RCTs are presented in Table 1. We further gathered 4 additional pilot studies for reference: Hsieh et al,³⁷ Bao et al,³⁸ Garcia et al,³⁹ and Schroeder et al⁴⁰ (Table 2).

Figure 1.

Studies selection flowchart, which is based on the PRISMA Statement.²⁸

Table 1.

The Characteristics of the Included RCTs.

Study, Trial Type	Sample No./Nation/Language	Included Cancer Type/Chemo-Regimen	Experimental/Control Arm	Intervention (Primary Acupoints)	Acupuncture Schedule	Measurement Tools	Result
Molassiotis et al,³¹ RCT	87/Hong Kong/English	All cancer/platinum, taxane, bortezomib, oxalip	Wait list control	Upper limbs: LI4, LI11, PC7, TE5, and/or Baxie points; lower limbs: SP6, ST36, LV3, ST41, and/or Bafeng (Ex-LE10)	Twice weekly for 8 weeks	BPI	Significant changes noted in pain, intensity, and pain interference
						FACT/NTX	The TNSc (combination of sensory tests/neurological assessment, signs and symptoms) was significantly improved (P < .05)
						TNSc	Physical well-being (P < .01), functional well-being (P < .05), neurotoxicity subscale score (P < .01), the FACT/GOG-NTX Trial Outcome Index (P < .001)
						NCV
Han et al,³³ RCT	98/China/English	Multiple myeloma/bortezomib	Acu + Mec:Mec	LR3; ST43; GB41; SP6; ST36; SP10 ST25; GV14; GV12	QD for 3 days, then QOD for 10 days, per 28 days; repeat 3 cycles; total 12 weeks	Pain: VAS	VAS decreased more significantly in Acu group than in control group (P < .01)
						FACT/NTX	FACT/the GOG-NTX: nervous system symptoms improved significantly in the Met + Acu group (P < .001) after therapy, but not in the control group (P > .05)
						NCV	NCV: benefit noted within Acu group (P < .01); yet not significantly better compared with control group
Zhang et al,³⁴ RCT	38/China/English	All cancer/platinum, taxane, bortezomib, oxalip vinblastine-etoposide	EA:A	Hegu (LI 4); Taichong (LR 3) with De-Qi	Once per day starting at the day before chemotherapy for consecutive 7 days followed by 14 days off, with 21 days as a course of treatment	Peripheral neuropathy: specific grading system of Levi	Specific grading system of Levi: electroacupuncture is better (P = .007)
						Traditional Chinese clinical symptoms, life quality	Quality of life: electroacupuncture is better than acupuncture (P < .001)
						Immune cytokine	The traditional Chinese clinical symptoms: electroacupuncture is better (P < .001)
						Immune cytokine	Immune cytokine: no statistical significance between these comparison (P > .05)
Lu et al,³⁵ RCT	40/USA/English	Breast cancer/adjuvant chemotherapy regimen	Acu + usual care: usual care	LI11, TW5, Baxie, SP9, ST36, SP9, LR3, KI3	18 Sessions of a standardized acupuncture protocol over 8 weeks	PNQ	Acupuncture is superior than control with regard to
						PNQ	PNQ (P = .01)
						FACT-NTX	FACT-NTX (P = .002)
						EORTC QLQ-CIPN20	EORTC QLQ-CIPN20 (P = .01)
						BPI-SF	BPI-SF (P = .01)
Greenlee et al,³² RCT	63/USA/English	Breast cancer/taxane (paclitaxel and docetaxel)	EA:Sham -EA	GB34, ST36, LI4, LI10, L3, L5, C5/C7 (Huatuojiaji 華佗夾脊); Ba xie points	12 Weekly true EA or sham EA concurrent with taxane treatment. Follow 16 weeks	BPI-SF	Pain: No differences in BPI-SF
						FACT-NTX	No differences in FACT-NTX at 6, 12, and 16 weeks
						NPS-4 scale	EA arm reported worse pain in the NPS-4 scale
						FACT-TAX	No differences between groups in the FACT-TAX, biothesiometer, or grooved pegboard tests
Rostock et al,³⁶ RCT	60/Germany/English	All cancer/taxanes, platinum derivatives, or vinca alkaloids	EA:HB: vitamin B: placebo	LV3, SP9, GB41, GB34, LI4, LI11, SI3, HT3	8 ± 1 sessions of EA; each session included 15 minutes of electrostimulation (50 Hz)	Neuropathic symptoms on a NRS	No significant improvement over EA: other group in neuropathy symptom improvement (P > .05)
						Neuropathy score	The effect is unclear in CIPN
						EORTC QLQ-C30	The effect is unclear in CIPN

Abbreviations: RCT, randomized controlled trial; LI, liver meridian; SP, spleen; BPI, Brief Pain Inventory; FACT/NTx, Functional Assessment of Cancer Therapy/Neurotoxicity Questionnaire; TNSc, Total Neuropathy Score–Clinical Version; NCV, nerve conduction velocity; EA, electroacupuncture; GOG, gynecologic oncology group; Acu, acupuncture; Mec, mechanisms; QD, twice a day; QOD, every other day; VAS, Visual Analog Scale; PNQ, Patient Neurotoxicity Questionnaire; EORTC QLQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; CIPN, chemotherapy-induced peripheral neuropathy; BPI-SF, Brief Pain Inventory–Short Form; NPS, Neuropathy Pain Scale; TAX, taxane; NRS, Numerical Rating Scale.

Table 2.

Pilot Study of Acupuncture in Chemotherapy Induced Neuropathy.

Study, Trial Type	Sample No./Nation/Language	Cancer Type/Chemotherapy Regimen	Intervention (Primary Acupoints)	Acupuncture Schedule	Measurement Tools	Result
Hsieh et al³⁷, pilot study	17/Taiwan/English	Colon and gastric cancer/oxaliplatin based	PC6, PC7, PC8, P9, LU11, SP6, KI3, BL60, KI1, and KI2	3 Times per week for 4 consecutive weeks (total of 12 sessions over 4 weeks with laser acupuncture)	OSNS	PQAS, CINQ, and OSNS scores, as well as touch-detection threshold and cold-trigger pain withdrawal latency all improved significantly
					PQAS
					CINQ
Bao et al³⁸, pilot study	27/USA/English	Multiple myeloma/bortezomib	LI4, TE5, LI11, ST40, Ba Feng	2 Times per week for 2 weeks, 1 time per week for 4 weeks, and then biweekly for 4 weeks. Total 10 weeks	FACT/NTX	FACT/NTX score improved (P < .0001); mean NPS scores also decreased significantly (P < .0001). No significant changes in any of the 12 cytokines.
					NPS
					Proinflammatory cytokines
Garcia et al,³⁹ feasibility study	19/USA/English	Multiple myeloma/thalidomide, bortezomib	LV3, SP6, GB42, ST36, LI4, SI3 CV4, CV6	20 Times acupuncture treatment over 9 weeks	FACT/NTX, BPI-SF, NCS	FACT//NTX significantly improved (P = .002). No significant changes were seen with NCS.
Schroeder et al,⁴⁰ pilot study	6/Germany/English	Unlimited cancer type	ST34, EX-LE12, EX-LE8	A standard 10-weekly acupuncture with de qi	Nerve conduction study	Positive effect on CIPN

Abbreviations: OSNS, Oxaliplatin-Specific Neurotoxicity Scale; PQAS, Pain Quality Assessment Scale; CINQ, Chemotherapy-Induced Neurotoxicity Questionnaire; FACT/NTX, Functional Assessment of Cancer Therapy/Neurotoxicity questionnaire; NPS, Neuropathy Pain Scale; BPI-SF, Brief Pain Inventory–Short Form; NCS, nerve conduction study; CIPN, chemotherapy-induced peripheral neuropathy.

The Risk of Bias and Quality Assessment

The quality of each enrolled study was assessed independently by 2 reviewers, adopting the criteria recommended in the Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0.⁴¹ Six domains were assessed: (1) generation of randomization, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data, and (6) selective outcome reporting. We assessed the quality of the included studies using the modified Jadad scale.^42,43 The modified Jadad scale represents the quality of RCT, awarding a maximum of 5 points (1 point each for randomization, appropriate randomization method, describing dropouts, patient blinding, and assessor blinding). When data were missing or incomplete, we contacted authors to identify additional studies and asked them to provide methodological details.

Data Synthesis and Statistical Meta-Analysis

To analyze the effects of acupuncture on consistent outcomes (mean change in BPI-SF and FACT-NTX scores) and NCV after treatment compared with baseline, we estimated the weighted mean differences and 95% confidence intervals (CIs) from each study using the Cochrane Collaboration’s software, Review Manager (RevMan) Version 5.2 for Windows (The Nordic Cochrane Centre, Copenhagen, Denmark). For weighted mean differences, a point estimate of zero reflected “no effect,” and less than zero favored the acupuncture intervention. Statistical heterogeneity was assessed by using the χ² test (P < .1). The I² statistic was also calculated, and we considered I² > 50% to indicate significant heterogeneity across studies.⁴⁴ A random-effects model was used if significant heterogeneity was shown in the included trials. Otherwise, results were obtained from a fixed-effects model. The results of other outcomes measures are shown in Table 1.

Results

Evaluation of Quality and Descriptions of the Included Trials

Table 3 shows the risk of bias in the 6 included studies. Most studies had a low risk for all domains, indicating a convincing quality of this systematic review. The quality of included studies was high, in that 3 studies had scores of 5, and 3 had scores of 4 on the modified Jadad scale.

Table 3.

Risk of Bias in the Included Trials^a.

Study	Randomization	Allocation Concealment	Patients Blinding	Assessor Blinding	Incomplete Outcome Data Addressed	Selective Outcome Reporting	Modified Jaded Scale
Molassiotis et al³¹	Low	Low	Low	Low	Low	Low	5
Hann et al³³	Low	Low	Low	Uncertain	Low	Low	4
Lu et al³⁵	Low	Low	Low	Uncertain	Low	Low	4
Greenlee et al³²	Low	Low	Low	Low	Low	Low	5
Zhang et al³⁴	Low	Low	Low	High	Low	Low	4
Rostock et al³⁶	Low	Low	Low	Low	Low	Low	5

Modified Jadad Scale: Jadad et al.⁴²

The 6 randomized clinical trials included 386 patients with CIPN (Table 1). Sample sizes ranged from 38 to 98. The control treatments varied from blank control to sham acupuncture, usual care, and vitamin B or methylcobalamin. Some RCTs had more than one control group. The heterogeneity and limited number of studies may contribute to some risk of bias. Table 3 shows the risk of bias in each of 6 domains, and Figure 2 demonstrates the risk of bias graph of included trials. Nevertheless, we included only studies with consistent outcomes for meta-analysis, in order to reach valid results.

Figure 2.

Risk of bias graph of included trials.

Effects of Acupuncture on CIPN Symptoms

Owing to the small number studies, we did not perform funnel plots and publication bias cannot be excluded. We observed significant between-study heterogeneity in the effects of acupuncture on neuropathy symptoms and quality of life (I² = 89% and 36%, respectively). As for the 3 trials that reported pain scores, a significant reduction in the BPI-SF mean worst pain score was observed in subjects treated with acupuncture (−1.21, 95% CI = −1.61 to −0.82, P < .0001; Figure 3A) as compared with control subjects. For the 4 trials that reported Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group/Neurotoxicity scores,^29,30 subjects receiving acupuncture showed significant improvement in nervous system symptoms (−2.02, 95% CI = −2.21 to −1.84, P < .00001; Figure 3B) as compared with control subjects. However, for the 2 trials that reported sensory NCV of the sural nerve, no significant change in NCV was observed in subjects treated with acupuncture (1.58, 95% CI = −2.67 to 5.83, P = .47; Figure 3C) as compared with controls.

Figure 3.

(A) Forest plot of the effect of acupuncture on the BPI-SF worst pain score of chemotherapy-induced peripheral neuropathy. (B) Forest plot of the effect of acupuncture on the FACT-NTX score of chemotherapy-induced peripheral neuropathy. (C) Forest plot of the effect of acupuncture on the sensory nerve conduction velocity of sural nerve for chemotherapy-induced peripheral neuropathy.

Discussion

The application of acupuncture to CIPN is important, since the condition currently has no definitive treatment. According to the studies we reviewed, acupuncture has the potential to improve quality of life in terms of pain score and FACT-NTX assessment, yet no difference in NCV or relevant serum cytokines has been reported.

Among the 6 RCTs collected in our systematic review, 4 found a positive effect of acupuncture on CIPN. The negative studies raise questions about different effects across acupuncture modalities, utility, and timing.

Since the outcome measurements were not consistent across studies, only BPI-SF, FACT-NTX, and NCV could be used for meta-analysis. In the qualified enrolled studies, we found positive effects of acupuncture in these variables. Individually, Molassiotis et al³¹ and Han et al³³ concluded that acupuncture can improve quality of life and neuropathy, while Greenlee et al³² noted an inferior effect of acupuncture compared with sham control, and Rostock et al,³⁶ who used a 4-arm study, deemed the efficacy of acupuncture unclear. Zhang et al³⁴ found electroacupuncture superior to acupuncture in terms of symptom relief and quality of life improvement in treating bortezomib-related neuropathy. Others found a positive effect for bortezomib-induced neuropathy^33,38,39 but a negative effect for taxane used for breast cancer.³² Despite these findings, the limited number of studies prevents drawing any definite conclusions about the efficacy of acupuncture. We further reviewed the relevant pilot studies of acupuncture on chemotherapy-induced nausea and vomiting, some designed to target bortezomib-related neuropathy but others not restricted by type of chemo-regimen. However, only Zhang et al³⁴ used objective measures such as proinflammatory cytokines, and they showed no difference after acupuncture.

The cause and progression of CIPN involves multiple mechanisms according to drug type. For taxanes, the cause is attributed to disruption of the microtubule structure, which leads to impairment of axoplasmic transport and dying-back neuropathy.^45,46 Bortezomib damages the dorsal root ganglia neuronal cell bodies, leading to peripheral nerve degeneration.⁴⁷ The mechanism of neuropathy related to thalidomide or lenalidomide is uncertain, although most complaints are sensory impairment, with some autonomic neuropathy also being noted.⁴⁸ Platinum derivatives, the most commonly used regimen, have been noted to be retained in the dorsal root ganglion cells with reduction in nuclear size.⁴⁹ Other chemo-regimens that lead to neuropathy include ixabepilone and vinca-alkaloids. These regimens interfere with axonal transport⁵⁰ or produce a loss of axonal microtubules and alterations in their length, arrangement, and orientation.⁵¹ In most cases, the neurotoxicity is related to the accumulating dose and use period, yet none of the studies addressed the accumulated dose of the chemo-regimen.

Previous research does not indicate whether acupuncture can accelerate neuron recovery. One study found that the efficacy of acupuncture in oxaliplatin-induced neuropathy works through activation of the serotonergic system, especially spinal 5-HT3 receptors.⁵² Another study claimed that acupuncture can alter sensory perception, reducing the pain evoked by blunt pressure or the perception of noxious heat or cold.⁵³ In short, acupuncture can reduce CIPN to some extent via improving symptoms, but the mechanism is not clear. Finally, many studies have noted that polymorphisms of genes play an important role in CIPN, which might affect the drug metabolism⁵⁴ or the relevant repair mechanisms and inflammation.⁵⁵ In short, our current understanding of CIPN is in its infancy. Nevertheless, our study showed that acupuncture is safe and has great potential in relieving symptoms, although large-scale studies remain to be conducted.

As for the choice of acupoints, different trials adopted diverse acupoints complex without consistency. This issue had been noted for a period time since in different topics about acupuncture-related meta-analysis, choice of acupoints always varied in included RCTs. However, we noted in this topic that some common acupoints are categorized to spleen (SP6, SP10) and liver (LI4, LI11) meridians. We supposed that the spleen and liver meridians circulate to breast area, whereas another important acupoint, ST36 (ZuSanLi), is famous in boosting overall immunity and vitality, the so called Qi (氣).⁵⁶ Anyway, it is hard to have a definite and consistent prescription in acupoints selection in clinical trials in certain diseases, yet some articles also discuss whether De-Qi is no less important than acupoints selection.⁵⁷

To our knowledge, this is the first systematic review of the effect of acupuncture in chemotherapy-related neuropathy. Clinical trials have demonstrated that there is no unequivocal gold standard for the prevention and treatment of CIPN.⁵⁸ Several neuroprotective agents including thiols, neurotrophic factors, anticonvulsants, and antioxidants have been tested in preclinical models and RCTs for their ability to prevent or treat symptoms of CIPN.⁵⁹ Although agents like vitamin E, glutamine, glutathione, N-acetylcysteine, oxcarbazepine, and xaliproden have shown promise, convincing evidence for their efficacy is still lacking.⁶⁰ In this context, we assume that acupuncture is a feasible and promising method for its safety and noninvasive approach, which in turn means patients can avoid taking more drugs and risking further drug interaction. However, research relevant to this issue is limited and the control arms are varied; furthermore, more quantitative tools, such as NCV examinations,⁶¹ verified cytokines targeted to a specified regimen^31,62 and image studies^63,64 such as functioning magnetic resonance imaging could provide more objective evidence and warrant scholars’ consideration in the future.⁶⁵

Last, from the perspective of Chinese medicine, acupuncture promotes the flow of Qi (氣), which reconciles the Yin-Yang and thus improves both symptoms and pain; this theory, though, is difficult to prove. A critical drawback to clinical trials of acupuncture is that researchers have reached no consensus on what constitutes a consistent acupuncture schedule, including acupoint selection, treatment course, and frequency. Given the need for individualized treatment, a basic consistency in schedule will further the crosstalk between acupuncture and modern medicine. We observed that an acupuncture protocol for peripheral neuropathy was published in 2017, which implies some progress in this area.⁶⁶

Limitations

One limitation of this systematic review is the limited number of trials, despite the timeliness of the topic. The variety in control arms may also have led to some bias in explaining the results. The outcome measurements were not consistent, complicating the analysis. Additionally, the result will be more convincing with a larger number of cases; nevertheless, acupuncture shows promise in its ability to deal with CIPN due to its safety and previous evidence-based efficacy in pain relief and neuromodulation. In terms of its use in CIPN, further large-scale, regimen-targeted design, randomized studies are warranted. From an objective perspective, if more medical centers can join together to conduct a similar study in one country or even in different countries, that will promote the traditional Chinese medicine–related research and lead to more convincing results.

Conclusion

This meta-analysis of the efficacy of acupuncture in CIPN reveals that acupuncture can reduce pain and improve quality of life (FACT-NTX score). However, we cannot yet recommend a definite acupuncture protocol from the limited number of studies reviewed here. Future study design will need to include more quantitative end points, such as completed NCV, quantitative sensory testing or proinflammatory cytokines, and neurotrophic factors. Considering the safety and lack of serious adverse effects associated with acupuncture and the lack of a definite treatment for CIPN, acupuncture could be considered for treating CIPN.

Supplemental Material

S1_Appendix._Search_Strategy_20190919 – Supplemental material for The Efficacy of Acupuncture in Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Meta-Analysis

Supplemental material, S1_Appendix._Search_Strategy_20190919 for The Efficacy of Acupuncture in Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Meta-Analysis by Tsai-Ju Chien, Chia-Yu Liu, Ching-Ju Fang and Chun-Yu Kuo in Integrative Cancer Therapies

Supplemental Material

S2_Appendix._PRISMA_2009_Checklist – Supplemental material for The Efficacy of Acupuncture in Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Meta-Analysis

Supplemental material, S2_Appendix._PRISMA_2009_Checklist for The Efficacy of Acupuncture in Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Meta-Analysis by Tsai-Ju Chien, Chia-Yu Liu, Ching-Ju Fang and Chun-Yu Kuo in Integrative Cancer Therapies

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by grants from Ministry of Science and Technology, 108-2320-B-532-001-MY3.

ORCID iDs

Tsai-Ju Chien

Ching-Ju Fang

Supplemental Material

Supplemental material for this article is available online.

References

Ben-Horin

Kahan

Ryvo

Inbar

Lev-Ari

Geva

Acupuncture and reflexology for chemotherapy-induced peripheral neuropathy in breast cancer. Integr Cancer Ther. 2017;16:258-262. doi:10.1177/1534735417690254

Butkovic

Tot

OK.

Laser acupuncture treatment of neuropathic pain in a boy with brain tumour. Complement Ther Med. 2017;35:53-56. doi:10.1016/j.ctim.2017.09.006

Windebank

Grisold

Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13:27-46. doi:10.1111/j.1529-8027.2008.00156.x

Cavaletti

Cornblath

Merkies

, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol. 2013;24:454-462. doi:10.1093/annonc/mds329

Zhou

Garcia

Chang

, et al. Multiple myeloma, painful neuropathy, acupuncture? Am J Clin Oncol. 2009;32:319-325. doi:10.1097/COC.0b013e318173a520

Park

Goldstein

Krishnan

, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63:419-437. doi:10.3322/caac.21204

Long

Gao

Ping

BH.

Effect of omega-3 fish oil fat emulsion on the peripheral neuropathy caused by bortezomib [in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2011;32:633-634.

Schloss

Colosimo

B vitamin complex and chemotherapy-induced peripheral neuropathy. Curr Oncol Rep. 2017;19:76. doi:10.1007/s11912-017-0636-z

Wang

Lin

, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist. 2007;12:312-319. doi:10.1634/theoncologist.12-3-312

10.

Sands

Ladas

Kelly

, et al. Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. Support Care Cancer. 2017;25:701-708. doi:10.1007/s00520-016-3441-6

11.

Moody

Marx

Hammerstrom

Treatment of chemotherapy-induced peripheral neuropathy in integrative oncology: a survey of acupuncture and oriental medicine practitioners. J Altern Complement Med. 2017;23:964-970. doi:10.1089/acm.2017.0052

12.

Visovsky

Acupuncture for the management of chemotherapy-induced peripheral neuropathy. J Adv Pract Oncol. 2012;3:178-181.

13.

Liang

Chen

Cooper

EL.

Neuroendocrine mechanisms of acupuncture. Evid Based Complement Alternat Med. 2012;2012:792793. doi:10.1155/2012/792793

14.

Litscher

Bioengineering assessment of acupuncture, Part 6: monitoring—neurophysiology. Crit Rev Biomed Eng. 2007;35:1-36.

15.

Rosenthal

DS.

Acupuncture for cancer pain and related symptoms. Curr Pain Headache Rep. 2013;17:321. doi:10.1007/s11916-013-0321-3

16.

Paley

Tashani

Bagnall

Johnson

MI.

A Cochrane systematic review of acupuncture for cancer pain in adults. BMJ Support Palliat Care. 2011;1:51-55. doi:10.1136/bmjspcare-2011-000022

17.

Deng

Chan

Sjoberg

, et al. Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial. Support Care Cancer. 2013;21:1735-1741. doi:10.1007/s00520-013-1720-z

18.

Nian

Sun

Guo

, et al. Efficacy and safety of acupuncture for chemotherapy-induced leucopoenia: protocol for a systematic review. BMJ Open. 2016;6:e010787. doi:10.1136/bmjopen-2015-010787

19.

Chien

Hsu

Liu

Fang

CJ.

Effect of acupuncture on hot flush and menopause symptoms in breast cancer—a systematic review and meta-analysis. PLoS One. 2017;12:e0180918. doi:10.1371/journal.pone.0180918

20.

Chien

Liu

Chang

Fang

Hsu

CH.

Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis. J Altern Complement Med. 2015;21:251-260. doi:10.1089/acm.2014.0083

21.

Enblom

Steineck

Hammar

Borjeson

Reduced need for rescue antiemetics and improved capacity to eat in patients receiving acupuncture compared to patients receiving sham acupuncture or standard care during radiotherapy. Evid Based Complement Alternat Med. 2017;2017:5806351. doi:10.1155/2017/5806351

22.

Johnstone

Peng

May

Inouye

Niemtzow

. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys. 2001;50:353-357.

23.

Zhang

Yan

Clinical effects of acupuncture for diabetic peripheral neuropathy. J Tradit Chin Med. 2010;30:13-14.

24.

Zhong

Guo

Wang

, et al. Discussion of acupuncture for diabetic peripheral neuropathy based on blood stasis theory [in Chinese]. Zhongguo Zhen Jiu. 2017;37:199-201. doi:10.13703/j.0255-2930.2017.02.027

25.

Dimitrova

Murchison

Oken

Local effects of acupuncture on the median and ulnar nerves in patients with carpal tunnel syndrome: a pilot mechanistic study protocol. Trials. 2019;20:8. doi:10.1186/s13063-018-3094-5

26.

Hadianfard

Bazrafshan

Momeninejad

Jahani

Efficacies of acupuncture and anti-inflammatory treatment for carpal tunnel syndrome. J Acupunct Meridian Stud. 2015;8:229-235. doi:10.1016/j.jams.2014.11.005

27.

Moher

Liberati

Tetzlaff

Altman

; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi:10.1371/journal.pmed.1000097

28.

Liberati

Altman

Tetzlaff

, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. doi:10.1371/journal.pmed.1000100

29.

Driessen

de Kleine-Bolt

Vingerhoets

Mols

Vreugdenhil

Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer. 2012;20:877-881. doi:10.1007/s00520-011-1336-0

30.

Chu

Lee

Cleeland

CS.

Properties of the measures to assess oxaliplatin-induced peripheral neuropathy: a literature review [in Korean]. J Korean Acad Nurs. 2015;45:783-801. doi:10.4040/jkan.2015.45.6.783

31.

Molassiotis

Suen

LKP

Cheng

, et al. A randomized assessor-blinded wait-list-controlled trial to assess the effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Integr Cancer Ther. 2019;18:1534735419836501. doi:10.1177/1534735419836501

32.

Greenlee

Crew

Capodice

, et al. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Res Treat. 2016;156:453-464. doi:10.1007/s10549-016-3759-2

33.

Han

Wang

Shi

, et al. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. BMC Cancer. 2017;17:40. doi:10.1186/s12885-016-3037-z

34.

Zhang

, et al. Effect of electroacupuncture on chemotherapy-induced peripheral neuropathy in patients with malignant tumor: a single-blinded, randomized controlled trial. J Tradit Chin Med. 2017;37:179-184.

35.

Giobbie-Hurder

Freedman

, et al. Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer, preliminary results of a pilot randomized controlled trial. Cancer Res. 2017;77:PD4-01. doi:10.1158/1538-7445.SABCS16-PD4-01

36.

Rostock

Jaroslawski

Guethlin

Ludtke

Schroder

Bartsch

HH.

Chemotherapy-induced peripheral neuropathy in cancer patients: a four-arm randomized trial on the effectiveness of electroacupuncture. Evid Based Complement Alternat Med. 2013;2013:349653. doi:10.1155/2013/349653

37.

Hsieh

Chou

Hong

, et al. Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study. Acupunct Med. 2016;34:398-405. doi:10.1136/acupmed-2016-011112

38.

Bao

Goloubeva

Pelser

, et al. A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Integr Cancer Ther. 2014;13:396-404. doi:10.1177/1534735414534729

39.

Garcia

Cohen

Guo

, et al. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014;7:41. doi:10.1186/1756-8722-7-41

40.

Schroeder

Meyer-Hamme

Epplee

Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct Med. 2012;30:4-7. doi:10.1136/acupmed-2011-010034

41.

Higgins

JPT

Green

. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. https://training.cochrane.org/handbook/archive/v5.1/. Updated March 2011. Accessed October 19, 2019.

42.

Jadad

Moore

Carroll

, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.

43.

Gao

Liu

Zhang

Upur

Effect of Jianpi therapy in treatment of chronic obstructive pulmonary disease: a systematic review. J Tradit Chin Med. 2013;33:1-8.

44.

Higgins

Thompson

Deeks

Altman

DG.

Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560. doi:10.1136/bmj.327.7414.557

45.

Xiao

Zheng

Bennett

GJ.

Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience. 2012;203:194-206. doi:10.1016/j.neurosci ence.2011.12.023

46.

Flatters

Bennett

GJ.

Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006;122:245-257. doi:10.1016/j.pain.2006.01.037

47.

Cavaletti

Gilardini

Canta

, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol. 2007;204:317-325. doi:10.1016/j.expneurol.2006.11.010

48.

Plasmati

Pastorelli

Cavo

, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007;69:573-581. doi:10.1212/01.wnl.0000267271.18475.fe

49.

McKeage

Hsu

Screnci

Haddad

Baguley

BC.

Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer. 2001;85:1219-1225. doi:10.1054/bjoc.2001.2024

50.

Schiff

Wen

van den Bent

MJ.

Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol. 2009;6:596-603. doi:10.1038/nrclinonc.2009.128

51.

Lobert

Vulevic

Correia

JJ.

Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry. 1996;35:6806-6814. doi:10.1021/bi953037i

52.

Lee

Yoon

, et al. Serotonergic mechanism of the relieving effect of bee venom acupuncture on oxaliplatin-induced neuropathic cold allodynia in rats. BMC Complement Altern Med. 2014;14:471. doi:10.1186/1472-6882-14-471

53.

Baeumler

Fleckenstein

Takayama

Simang

Seki

Irnich

Effects of acupuncture on sensory perception: a systematic review and meta-analysis. PLoS One. 2014;9:e113731. doi:10.1371/journal.pone.0113731

54.

Cavaletti

Alberti

Marmiroli

Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011;12:1151-1161. doi:10.1016/S1470-2045(11)70131-0

55.

Johnson

Corthals

Walker

, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011;29:797-804. doi:10.1200/JCO.2010.28.0792

56.

Chen

Yin

, et al. Enhancement of immune cytokines and splenic CD4+ T cells by electroacupuncture at ST36 acupoint of SD rats. PLoS One. 2017;12:e0175568. doi:10.1371/journal.pone.0175568

57.

Yang

Shi

Zhang

Liu

CZ.

Characterization of deqi sensation and acupuncture effect. Evid Based Complement Alternat Med. 2013;2013:319734. doi:10.1155/2013/319734

58.

Poupon

Kerckhove

Vein

, et al. Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives. Expert Opin Drug Saf. 2015;14:1269-1282. doi:10.1517/14740338.2015.1056777

59.

Argyriou

Zolota

Kyriakopoulou

Kalofonos

HP.

Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents. J BUON. 2010;15:435-446.

60.

Wolf

Barton

Kottschade

Grothey

Loprinzi

Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44:1507-1515. doi:10.1016/j.ejca.2008.04.018

61.

Brown

Pribesh

Baskette

Vinik

Colberg

SR.

A comparison of screening tools for the early detection of peripheral neuropathy in adults with and without type 2 diabetes. J Diabetes Res. 2017;2017:1467213. doi:10.1155/2017/1467213

62.

Al-Mazidi

Alotaibi

Nedjadi

Chaudhary

Alzoghaibi

Djouhri

Blocking of cytokines signalling attenuates evoked and spontaneous neuropathic pain behaviours in the paclitaxel rat model of chemotherapy-induced neuropathy. Eur J Pain. 2018;22:810-821. doi:10.1002/ejp.1169

63.

Chen

Sun

Chen

, et al. Integrating image-based high-content screening with mouse models identifies 5-hydroxydecanoate as a neuroprotective drug for paclitaxel-induced neuropathy. Mol Cancer Ther. 2015;14:2206-2214. doi:10.1158/1535-7163.MCT-15-0268

64.

Guo

Hamre

3rd Eldridge

, et al. Editor’s highlight: multiparametric image analysis of rat dorsal root ganglion cultures to evaluate peripheral neuropathy-inducing chemotherapeutics. Toxicol Sci. 2017;156:275-288. doi:10.1093/toxsci/kfw254

65.

Langjahr

Schubert

Sommer

Uceyler

Increased pro-inflammatory cytokine gene expression in peripheral blood mononuclear cells of patients with polyneuropathies. J Neurol. 2018;265:618-627. doi:10.1007/s00415-018-8748-4

66.

Dimitrova

Introducing a standardized acupuncture protocol for peripheral neuropathy: a case series. Med Acupunct. 2017;29:352-365. doi:10.1089/acu.2017.1242

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.17 MB

0.20 MB